Serum soluble signal regulatory protein alpha as a potential prognostic biomarker after surgery for esophageal cancer.

Authors

Kristian W Antonsen, Niels Katballe, Daniel W Kjær, Thomas D Christensen, Holger J Møller, Tua Gyldenholm

Published in

Clinical immunology (Orlando, Fla.). Pages 110784. Oct 07, 2026. Epub Oct 07, 2026.

Abstract

Signal Regulatory Protein Alpha (SIRPα) and CD163 are associated with prognosis in esophageal cancer, but their prognostic value in blood is unknown. We retrospectively analyzed a randomized controlled trial of patients undergoing surgery for esophageal cancer. Soluble SIRPα (sSIRPα) and CD163 (sCD163) were measured using enzyme-linked immunosorbent assays in serum collected on the day of surgery and postoperative day 30. Patients were followed for one year. 68 patients were included. In patients undergoing upfront surgery (n = 15), high sSIRPα predicted increased 1-year mortality and sSIRPα <23.35 μg/L identified a low-risk subgroup (N = 7/15, 46.7%) with 100% 1-year survival. In contrast, among patients receiving neoadjuvant chemotherapy (CROSS or FLOT, n = 53), low sSIRPα predicted increased 1-year mortality and sSIRPα >26.15 μg/L identified a low-risk subgroup (N = 31/53, 58.5%) with 100% 1-year survival. There was no prognostic value in sCD163. In conclusion, neoadjuvant treatment may influence the prognostic value of sSIRPα in esophageal cancer.

PMID:
42843775
Bibliographic data and abstract were imported from PubMed on 08 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.